NEW YORK (GenomeWeb News) – NanoString Technologies has obtained the CE Mark for its PAM50-based gene expression test for breast cancer, clearing the firm to sell the test in the European Union and other countries that recognize the CE Mark. The test provides a subtype classification based on the fundamental biology of an individual's breast tumor and a prognostic score that predicts the probability of cancer recurrence over 10 years in post-menopausal women with hormone receptor-positive, early-stage breast cancer who have been treated with hormonal therapy.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.

Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.

Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.

In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.